Journal article
Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
Abstract
The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary survival and resource utilization data from a large three-arm randomized trial comparing: paclitaxel 135 mg m–2 by 24-h intravenous (i.v.) infusion + cisplatin; paclitaxel 250 mg m–2 by 24-h i.v. infusion …
Authors
Earle CC; Evans WK
Journal
British Journal of Cancer, Vol. 80, No. 5-6, pp. 815–820
Publisher
Springer Nature
Publication Date
5 1999
DOI
10.1038/sj.bjc.6690426
ISSN
0007-0920